Merkel细胞癌治疗新进展

doi:10.35541/cjd.20210536

中华皮肤科杂志 ›› 2023, e20210536.doi: 10.35541/cjd.20210536

Merkel细胞癌治疗新进展

杨爱民¹ 成将伟² 黄嘉诚¹ 岑瑛³ 陈俊杰³

¹四川大学华西临床医学院，成都 610044；²中国医科大学附属第一医院，沈阳 110001；³四川大学华西医院烧伤整形外科，成都 610044

收稿日期:2021-07-23 修回日期:2022-04-29 发布日期:2023-01-19
通讯作者: 岑瑛；陈俊杰 E-mail:cenyinghx@163.com; cjjemail@163.com
基金资助:
四川省科技计划重点研发项目（2020YFS0267）

Treatment of Merkel cell carcinoma

Yang Aimin¹, Chen Jiangwei², Huang Jiacheng¹, Cen Ying³, Chen Junjie³

¹West China School of Medicine, West China Hospital, Sichuan University, Chengdu 610044, China; ²The First Hospital of China Medical University, Shenyang 110001, China; ³Department of Burns and Plastic Surgery, West China Hospital, Sichuan University, Chengdu 610044, China

Received:2021-07-23 Revised:2022-04-29 Published:2023-01-19
Contact: Cen Ying; Chen Junjie E-mail:cenyinghx@163.com; cjjemail@163.com
Supported by:
Key Research and Development Projects of Sichuan Science and Technology Department（2020YFS0267）

摘要/Abstract

摘要： 【摘要】手术切除和放疗常规用于早中期Merkel细胞癌的治疗。近年来，针对晚期Merkel细胞癌，基于其免疫原性特征的免疫治疗已被证明有效。本文主要综述Merkel细胞癌的治疗进展，为其合理诊治提供参考。

关键词: 癌, Merkel细胞, 神经内分泌瘤, 梅克尔细胞多瘤病毒, 免疫疗法, 免疫检查点抑制剂

Abstract: 【Abstract】 Surgical resection and radiotherapy have been frequently applied to the treatment of early- and intermediate-stage Merkel cell carcinoma. In recent years, immunotherapy based on immunogenic characteristics of Merkel cell carcinoma has been proved to be effective in the treatment of advanced Merkel cell carcinoma. This review focuses on advances in the treatment of Merkel cell carcinoma, and provides a reference for its clinical diagnosis and treatment.

Key words: Carcinoma, Merkel cell, Neuroendocrine tumor, Merkel cell polyomavirus, Immunotherapy, Immune checkpoint inhibitor

杨爱民成将伟黄嘉诚岑瑛陈俊杰. Merkel细胞癌治疗新进展[J]. 中华皮肤科杂志, 2023,e20210536. doi:10.35541/cjd.20210536

Yang Aimin, Chen Jiangwei, Huang Jiacheng, Cen Ying, Chen Junjie. Treatment of Merkel cell carcinoma[J]. Chinese Journal of Dermatology,2023,e20210536. doi:10.35541/cjd.20210536

参考文献 29

［1］	Stang A, Becker JC, Nghiem P, et al. The association between geographic location and incidence of Merkel cell carcinoma in comparison to melanoma: an international assessment［J］. Eur J Cancer, 2018,94:47⁃60. doi: 10.1016/j.ejca.2018.02.003.
［2］	王志伟, 李伟人, 刘莉, 等. 皮肤Merkel细胞癌171例临床及病理回顾分析［J］. 中华皮肤科杂志, 2018,51（9）:695⁃698. doi: 10.3760/cma.j.issn.0412⁃4030.2018.09.020.
［3］	Walsh NM, Cerroni L. Merkel cell carcinoma: a review［J］. J Cutan Pathol, 2021,48（3）:411⁃421. doi: 10.1111/cup.13910.
［4］	Feng H, Shuda M, Chang Y, et al. Clonal integration of a polyomavirus in human Merkel cell carcinoma［J］. Science, 2008,319（5866）:1096⁃1100. doi: 10.1126/science.1152586.
［5］	Zur Hausen A, Rennspiess D, Winnepenninckx V, et al. Early B⁃cell differentiation in Merkel cell carcinomas: clues to cellular ancestry［J］. Cancer Res, 2013,73（16）:4982⁃4987. doi: 10. 1158/0008⁃5472.CAN⁃13⁃0616.
［6］	Sunshine JC, Jahchan NS, Sage J, et al. Are there multiple cells of origin of Merkel cell carcinoma?［J］. Oncogene, 2018,37（11）:1409⁃1416. doi: 10.1038/s41388⁃017⁃0073⁃3.
［7］	Kervarrec T, Aljundi M, Appenzeller S, et al. Polyomavirus⁃positive Merkel cell carcinoma derived from a trichoblastoma suggests an epithelial origin of this Merkel cell carcinoma［J］. J Invest Dermatol, 2020,140（5）:976⁃985. doi: 10.1016/j.jid.2019. 09.026.
［8］	Poulsen M. Merkel cell carcinoma of skin: diagnosis and management strategies［J］. Drugs Aging, 2005,22（3）:219⁃229. doi: 10.2165/00002512⁃200522030⁃00004.
［9］	Lebbe C, Becker JC, Grob JJ, et al. Diagnosis and treatment of Merkel cell carcinoma. European consensus⁃based interdisciplinary guideline［J］. Eur J Cancer, 2015,51（16）:2396⁃2403. doi: 10.1016/j.ejca.2015.06.131.
［10］	Stachyra K, Dudzisz⁃Śledź M, Bylina E, et al. Merkel cell carcinoma from molecular pathology to novel therapies［J］. Int J Mol Sci, 2021,22（12）:6305. doi: 10.3390/ijms22126305.
［11］	Poulsen M. Merkel⁃cell carcinoma of the skin［J］. Lancet Oncol, 2004,5（10）:593⁃599. doi: 10.1016/S1470⁃2045（04）01593⁃1.
［12］	Becker JC, Stang A, DeCaprio JA, et al. Merkel cell carcinoma［J］. Nat Rev Dis Primers, 2017,3:17077. doi: 10.1038/nrdp. 2017.77.
［13］	Xue Y, Thakuria M. Merkel cell carcinoma review［J］. Hematol Oncol Clin North Am, 2019,33（1）:39⁃52. doi: 10.1016/j.hoc. 2018.08.002.
［14］	Babadzhanov M, Doudican N, Wilken R, et al. Current concepts and approaches to Merkel cell carcinoma［J］. Arch Dermatol Res, 2021,313（3）:129⁃138. doi: 10.1007/s00403⁃020⁃02107⁃9.
［15］	Moshiri AS, Doumani R, Yelistratova L, et al. Polyomavirus⁃negative Merkel cell carcinoma: a more aggressive subtype based on analysis of 282 cases using multimodal tumor virus detection［J］. J Invest Dermatol, 2017,137（4）:819⁃827. doi: 10.1016/j.jid.2016.10.028.
［16］	Eng TY, Boersma MG, Fuller CD, et al. Treatment of Merkel cell carcinoma［J］. Am J Clin Oncol, 2004,27（5）:510⁃515. doi: 10. 1097/01.coc.0000135567.62750.f4.
［17］	Andruska N, Fischer⁃Valuck BW, Mahapatra L, et al. Association between surgical margins larger than 1 cm and overall survival in patients with Merkel cell carcinoma［J］. JAMA Dermatol, 2021,157（5）:540⁃548. doi: 10.1001/jamadermatol. 2021.0247.
［18］	Servy A, Maubec E, Sugier PE, et al. Merkel cell carcinoma: value of sentinel lymph⁃node status and adjuvant radiation therapy［J］. Ann Oncol, 2016,27（5）:914⁃919. doi: 10.1093/annonc/mdw035.
［19］	Sims JR, Grotz TE, Pockaj BA, et al. Sentinel lymph node biopsy in Merkel cell carcinoma: the Mayo Clinic experience of 150 patients［J］. Surg Oncol, 2018,27（1）:11⁃17. doi: 10.1016/j.suronc.2017.10.005.
［20］	Yusuf M, Gaskins J, Wall W, et al. Optimal adjuvant radiotherapy dose for stage I, II or III Merkel cell carcinoma: an analysis of the national cancer database［J］. Jpn J Clin Oncol, 2020,50（2）:175⁃184. doi: 10.1093/jjco/hyz153.
［21］	Dellambra E, Carbone ML, Ricci F, et al. Merkel cell carcinoma［J］. Biomedicines, 2021,9（7）:718. doi: 10.3390/biomedicines 9070718.
［22］	Harms PW, Harms KL, Moore PS, et al. The biology and treatment of Merkel cell carcinoma: current understanding and research priorities［J］. Nat Rev Clin Oncol, 2018,15（12）:763⁃776. doi: 10.1038/s41571⁃018⁃0103⁃2.
［23］	Samimi M, Kervarrec T, Touze A. Immunobiology of Merkel cell carcinoma［J］. Curr Opin Oncol, 2020,32（2）:114⁃121. doi: 10. 1097/CCO.0000000000000608.
［24］	Ah⁃Thiane L, Samimi M, Kervarrec T, et al. Complete spontaneous regression of primary Merkel cell carcinoma with tumoural infiltration: a systematic review［J］. Eur J Dermatol, 2021,31（3）:381⁃391. doi: 10.1684/ejd.2021.4065.
［25］	Bhanegaonkar A, Liu FX, Boyd M, et al. Real⁃world clinical outcomes in patients with locally advanced or metastatic Merkel cell carcinoma treated in U.S. oncology clinical practices: results from SPEAR⁃Merkel［J］. Oncologist, 2021,26（9）:e1633⁃e1643. doi: 10.1002/onco.13845.
［26］	Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy⁃refractory metastatic Merkel cell carcinoma: a multicentre, single⁃group, open⁃label, phase 2 trial［J］. Lancet Oncol, 2016,17（10）:1374⁃1385. doi: 10.1016/S1470⁃2045（16）30364⁃3.
［27］	Nghiem P, Bhatia S, Lipson EJ, et al. Three⁃year survival, correlates and salvage therapies in patients receiving first⁃line pembrolizumab for advanced Merkel cell carcinoma［J］. J Immunother Cancer, 2021,9（4）:e002478. doi: 10.1136/jitc⁃2021⁃002478.
［28］	Nghiem P, Bhatia S, Lipson EJ, et al. Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first⁃line therapy［J］. J Clin Oncol, 2019,37（9）:693⁃702. doi: 10.1200/JCO.18.01896.
［29］	Stege HM, Haist M, Schultheis S, et al. Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study［J］. Cancer Immunol Immunother, 2021,70（11）:3313⁃3322. doi: 10.1007/s00262⁃021⁃02925⁃4.

[1]	丁高中刘梦茜马伟李姗姗孙澜陈朝潮. 甲母质细胞癌1例[J]. 中华皮肤科杂志, 2024, 57(2): 165-167.
[2]	张俐施健葛鑫刘念念陈赛张冬梅缪旭. Brahma相关基因1与激活转录因子2相互作用对皮肤鳞状细胞癌细胞增殖、迁移和侵袭能力的影响[J]. 中华皮肤科杂志, 2023, 56(8): 724-736.
[3]	王媛王艺萌吴雯婷李婷婷王冠钰张春雷. 葡萄糖转运蛋白3在皮肤鳞状细胞癌中的表达及其对A431细胞增殖、侵袭及迁移的影响[J]. 中华皮肤科杂志, 2023, 56(5): 421-427.
[4]	杨永婷李婷婷康晓静. 黑素瘤免疫检查点抑制剂治疗相关的生物标志物研究进展[J]. 中华皮肤科杂志, 2023, 56(3): 278-283.
[5]	张良杨明霞陈娜陈柳青. 改良Mohs显微描记手术治疗小汗腺汗孔癌5例[J]. 中华皮肤科杂志, 2023, 56(2): 149-151.
[6]	何庆张涛王秀丽高兴华陈洪铎柳敏, 齐瑞群. 光线性角化病恶性进展相关生物标志物的研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20220284-e20220284.
[7]	李婷婷康晓静. 肠道菌群与黑素瘤免疫检查点抑制剂治疗的研究进展[J]. 中华皮肤科杂志, 2023, 56(2): 177-180.
[8]	王冠钰王艺萌李薇薇张春雷. 复发/难治性皮肤T细胞淋巴瘤的非化疗药物新选择[J]. 中华皮肤科杂志, 2023, 56(12): 1170-1173.
[9]	曹蒙洪安澜王焱方方. 儿童黑素瘤临床研究进展[J]. 中华皮肤科杂志, 2023, 56(11): 1074-1078.
[10]	李容陈崑张家安. 长链非编码RNA在皮肤鳞状细胞癌中的作用机制进展[J]. 中华皮肤科杂志, 2023, 56(10): 985-988.
[11]	李婷婷关猛猛赵娟康晓静. 单细胞转录组测序在黑素瘤研究中的应用[J]. 中华皮肤科杂志, 2023, 56(10): 977-981.
[12]	陈文静邵睿邹云敏孟中勤严翘宋琳毅孙建方陈浩. 黏液表皮样癌8例临床及病理分析[J]. 中华皮肤科杂志, 2022, 55(8): 665-668.
[13]	施雁庭黎皓郑捷曹华. 程序性细胞死亡蛋白1及其配体通路在特发性炎症性肌病中的研究进展[J]. 中华皮肤科杂志, 2022, 55(7): 633-636.
[14]	张宁李舒李敬. 免疫检查点抑制剂和靶向药物辅助治疗可切除黑素瘤疗效的网状Meta分析[J]. 中华皮肤科杂志, 2022, 55(7): 603-609.
[15]	李艳张选奋张文芳 . 基于Wnt/β联蛋白信号通路探讨EphB2抑制剂对皮肤鳞状细胞癌的影响及作用机制[J]. 中华皮肤科杂志, 2022, 55(4): 321-328.

Merkel细胞癌治疗新进展

Treatment of Merkel cell carcinoma

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 29

相关文章 15

Metrics

本文评价

推荐阅读 10